Relmada Therapeutics Inc. Faces Nasdaq Listing Challenge Due to Sub-$1 Share Price

Reuters

24 Jul

Relmada <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Faces Nasdaq Listing Challenge Due to Sub-$1 Share Price

Relmada Therapeutics Inc. has announced a regulatory issue regarding its listing on the Nasdaq Stock Market. The company received notice from Nasdaq that it failed to maintain a minimum bid price of $1 per share for 30 consecutive business days, as required by Nasdaq's listing rules. On July 22, 2025, Nasdaq approved the transfer of Relmada's listing to the Nasdaq Capital Market and granted an extension until January 19, 2026, to regain compliance. To meet the requirements, Relmada's stock must have a closing bid price of at least $1 for ten consecutive business days within the compliance period. The company is actively monitoring the situation and exploring measures to maintain its Nasdaq listing. However, there is no guarantee that compliance will be achieved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-066995), on July 23, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2553122815"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553122815\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2553122815?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-24 04:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553122815","market":"us","top_or_hot":-1,"title":"Relmada Therapeutics Inc. Faces Nasdaq Listing Challenge Due to Sub-$1 Share Price","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Faces Nasdaq Listing Challenge Due to Sub-$1 Share Price\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Relmada Therapeutics Inc. has announced a regulatory issue regarding its listing on the Nasdaq Stock Market. The company received notice from Nasdaq that it failed to maintain a minimum bid price of $1 per share for 30 consecutive business days, as required by Nasdaq's listing rules. On July 22, 2025, Nasdaq approved the transfer of Relmada's listing to the Nasdaq Capital Market and granted an extension until January 19, 2026, to regain compliance. To meet the requirements, Relmada's stock must have a closing bid price of at least $1 for ten consecutive business days within the compliance period. The company is actively monitoring the situation and exploring measures to maintain its Nasdaq listing. However, there is no guarantee that compliance will be achieved.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-066995), on July 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Relmada Therapeutics Inc. Faces Nasdaq Listing Challenge Due to Sub-$1 Share Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRelmada Therapeutics Inc. Faces Nasdaq Listing Challenge Due to Sub-$1 Share Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-24 04:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Faces Nasdaq Listing Challenge Due to Sub-$1 Share Price\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Relmada Therapeutics Inc. has announced a regulatory issue regarding its listing on the Nasdaq Stock Market. The company received notice from Nasdaq that it failed to maintain a minimum bid price of $1 per share for 30 consecutive business days, as required by Nasdaq's listing rules. On July 22, 2025, Nasdaq approved the transfer of Relmada's listing to the Nasdaq Capital Market and granted an extension until January 19, 2026, to regain compliance. To meet the requirements, Relmada's stock must have a closing bid price of at least $1 for ten consecutive business days within the compliance period. The company is actively monitoring the situation and exploring measures to maintain its Nasdaq listing. However, there is no guarantee that compliance will be achieved.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-066995), on July 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nNDL5DxrGV:1","article_id":"2553122815","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553122815","pubTimestamp":1753302685,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Relmada Therapeutics Inc. has announced a regulatory issue regarding its listing on the Nasdaq Stock Market. The company received notice from Nasdaq that it failed to maintain a minimum bid price of $1 per share for 30 consecutive business days, as required by Nasdaq's listing rules. On July 22, 2025, Nasdaq approved the transfer of Relmada's listing to the Nasdaq Capital Market and granted an extension until January 19, 2026, to regain compliance. To meet the requirements, Relmada's stock must have a closing bid price of at least $1 for ten consecutive business days within the compliance period. The company is actively monitoring the situation and exploring measures to maintain its Nasdaq listing. However, there is no guarantee that compliance will be achieved.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RLMD":"Relmada Therapeutics, Inc."},"translate_title":"Relmada Therapeutics Inc.因股价低于1美元而面临纳斯达克上市挑战","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLMD":0.9},"content_text":"Relmada Therapeutics Inc. Faces Nasdaq Listing Challenge Due to Sub-$1 Share Price\n    \n\n        Relmada Therapeutics Inc. has announced a regulatory issue regarding its listing on the Nasdaq Stock Market. The company received notice from Nasdaq that it failed to maintain a minimum bid price of $1 per share for 30 consecutive business days, as required by Nasdaq's listing rules. On July 22, 2025, Nasdaq approved the transfer of Relmada's listing to the Nasdaq Capital Market and granted an extension until January 19, 2026, to regain compliance. To meet the requirements, Relmada's stock must have a closing bid price of at least $1 for ten consecutive business days within the compliance period. The company is actively monitoring the situation and exploring measures to maintain its Nasdaq listing. However, there is no guarantee that compliance will be achieved.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-066995), on July 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}